Envestnet Asset Management Inc. Has $215,000 Holdings in Heska Corp (HSKA)
Envestnet Asset Management Inc. lifted its holdings in shares of Heska Corp (NASDAQ:HSKA) by 46.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,438 shares of the medical research company’s stock after buying an additional 776 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Heska were worth $215,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in HSKA. Teachers Advisors LLC raised its stake in shares of Heska by 11.6% during the 1st quarter. Teachers Advisors LLC now owns 10,590 shares of the medical research company’s stock worth $1,112,000 after buying an additional 1,097 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in shares of Heska during the 2nd quarter worth approximately $154,000. Great West Life Assurance Co. Can acquired a new position in shares of Heska during the 2nd quarter worth approximately $936,000. Arizona State Retirement System acquired a new position in shares of Heska during the 2nd quarter worth approximately $343,000. Finally, Rhumbline Advisers raised its stake in shares of Heska by 8.6% during the 2nd quarter. Rhumbline Advisers now owns 12,554 shares of the medical research company’s stock worth $1,281,000 after buying an additional 999 shares during the period. 80.89% of the stock is owned by institutional investors and hedge funds.
Heska Corp (NASDAQ HSKA) opened at $80.86 on Wednesday. Heska Corp has a 52 week low of $70.49 and a 52 week high of $115.00. The company has a market capitalization of $586.60, a price-to-earnings ratio of 42.34, a P/E/G ratio of 2.16 and a beta of 0.75.
Several research analysts have recently weighed in on HSKA shares. Raymond James Financial reaffirmed a “buy” rating on shares of Heska in a research note on Monday, December 4th. B. Riley reduced their target price on Heska from $96.50 to $93.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. BidaskClub raised Heska from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Aegis reaffirmed a “buy” rating on shares of Heska in a research note on Tuesday, December 19th. Finally, Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $113.30.
In related news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the transaction, the insider now directly owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.70% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/27/envestnet-asset-management-inc-has-215000-holdings-in-heska-corp-hska.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.